Eloxx Pharmaceuticals, Inc. balance sheet ELOX

Annual Quarterly

As of Jun 30, 2026, Eloxx Pharmaceuticals, Inc. had total assets of $63.4 million. Stockholders' equity was $46.4 million. It held $62.0 million in cash and investments against $0 of total debt, net cash of $62.0 million. The current ratio, current assets divided by current liabilities, was 3.74.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the same quarter a year earlier.

Q2 FY2026
Jun 30, 2026
Q1 FY2026
Mar 31, 2026
Q4 FY2025
Dec 31, 2025
Q3 FY2023
Sep 30, 2023
Q2 FY2023
Jun 30, 2023
Q1 FY2023
Mar 31, 2023
Q4 FY2022
Dec 31, 2022
Q3 FY2022
Sep 30, 2022
Assets
Cash
62
6
5
5
-80.6%
4
-85.6%
5
-87.7%
19
-54.6%
25
-53.2%
Cash and investments
62
6
5
5
-80.6%
4
-85.6%
5
-87.7%
19
-54.6%
25
-53.2%
Total current assets
63
9
5
6
-78.1%
5
-83.0%
6
-84.8%
20
-53.7%
26
-52.1%
Property and equipment, net
—
—
0
0
-50.2%
0
-31.6%
0
-30.6%
0
-21.8%
0
-4.0%
Total assets
63
9
5
6
-77.5%
6
-81.8%
7
-83.5%
21
-53.2%
27
-51.5%
Liabilities and equity
Accounts payable
3
3
3
3
+96.5%
3
+61.4%
2
-16.2%
3
+119.0%
2
-36.4%
Total current liabilities
17
16
17
23
+8.2%
21
+9.0%
19
+1.5%
23
+132.0%
22
+128.0%
Total liabilities
—
—
17
26
-18.1%
25
-21.0%
23
-26.4%
32
+39.7%
32
+42.3%
Stockholders' equity
46
-8
-12
-20
-302.4%
-19
-1126.3%
16
+39.4%
-11
-147.6%
-5
-115.1%
Debt
Debt due within a year
0
0
1
3
+11.4%
2
+102.3%
2
4
-24.0%
3
Long-term debt
—
—
0
3
-73.4%
3
-70.0%
4
-66.8%
9
-28.7%
10
-17.2%
Lease liabilities
—
—
0
0
-68.7%
0
-58.0%
1
-47.6%
1
-42.0%
1
-37.7%
Total debt
0
0
1
6
-57.1%
6
-54.6%
6
-53.5%
13
-28.4%
13
-1.0%
Net cash
62
6
4
-1
-108.8%
-2
-110.7%
-1
-105.1%
6
-75.3%
11
-71.3%
Ratios
Current ratio
3.74x
0.53x
0.31x
0.24x
0.25x
0.33x
0.87x
1.18x
Debt to equity
0.00x
—
—
—
—
0.38x
—
—
Return on equity
—
—
—
—
—
-188.27%
—
—
Return on assets
—
—
-113.76%
-338.99%
-407.11%
-426.04%
-170.74%
-155.65%
Book value per share
11.50
-1.49
-27.35
-9.25
-8.58
7.52
-4.92
-0.06
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
ELOX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Arlington, MA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1035354
Former names
Sevion Therapeutics, Inc. (until Dec 22, 2017); SENESCO TECHNOLOGIES INC (until Sep 29, 2014); NAVA LEISURE USA INC (until May 24, 1999)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.